Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Unilife Corp | d668908d8k.htm |
| EX-99.1 - EX-99.1 - Unilife Corp | d668908dex991.htm |
 Fiscal Year 2014
2 nd
Quarter Earnings Call
Exhibit 99.2
February 3, 2014 |
 2
This
presentation contains forward looking statements under the safe harbor
provisions of the US securities laws. These forward-looking statements are based
on management’s beliefs and assumptions and on information currently available
to our management.
Our management believes that these forward-looking statements are reasonable
as and when made. However you should not place undue reliance on any such
forward looking statements as these are subject to risks and uncertainties.
Please
refer to our press releases and our SEC filings for more information regarding the
use of forward looking statements.
Cautionary Note Regarding Forward-Looking Statements |
 Introduction
to
Q214
Earnings
Call
3 |
 Update on Signed
Contracts 4 |
 An
Expanding
Commercial
Pipeline
5
Multiple
customers
pursuing
multiple
products
across
multiple
platforms
Unifill
Finesse™
Unifill®
Unifill
Nexus™
Unifill
Allure™
Unifill
Select™
AutoMix
Presto™
EZMix
Genesis™
EZMix
Engage™
EZMix
Genesis™
Precision-Therapy™
Wearable Injector
Flex-Therapy ™
Wearable Injector
Ocu-ject ™
Depot-ject ™
Micro-ject ™
RITA™
auto-injector
LISA™
auto-injector
These products have not been evaluated by the FDA |
 Financial
Data •
Revenue growth of 411% compared to same period prior year
•
Period of sequential revenue growth quarter to quarter continues
•
Net loss per share (net and adjusted) is narrowing
•
Reducing SG&A, continued investment in R&D and operations
6
Three Months Ended
December 31,
Six Months Ended
December 31,
2013
2012
2013
2012
Revenues
$3.6MM
$0.7MM
$6.8MM
$1.4MM
Research & development
$7.8MM
$5.0MM
$14.2MM
$9.7MM
Selling, general & administrative
$6.7MM
$8.3MM
$13.2MM
$14.9MM
Net loss
$16.3MM
$14.6MM
$27.5MM
$27.1MM
Net loss per share –
diluted
$0.17
$0.19
$0.29
$0.35
Adjusted net loss
$8.3MM
$9.7MM
$15.4MM
$18.8MM
Adjusted net loss per share -
diluted
$0.08
$0.12
$0.16
$0.24 |
 7
Existing clean
room space
Installation of
new clean
rooms
Doubling our cleanroom production space in York, PA |
 Building
shareholder value 8
Sanofi
MedImmune
Hikma
Biodel
Novartis Others
•
Commercial supply
contracts
•
Customization and
clinical supply contracts
•
Revenue from customers
Device sales, customization
programs, upfront fees
•
Debt financing
•
New clean rooms
•
Continued expansion
production capacities
•
Current platforms
•
New products |
 Questions
|